Colonoscopy
Conditions
Keywords
Butorphanol, Visceral pain, Propofol, Gastroscopy, Colonoscopy
Brief summary
The total incidence of abdominal pain after colonoscopy is almost 50%. Butorphanol is a mixed opioid receptor agonist-antagonist, which has strong sedative and analgesic effects. This clinical study aims to explore the effectiveness and safety of butorphanol combined with propofol for colonoscopy to reduce postoperative visceral pain, and provide a basis for improving the quality of surgery and comfortable medical treatment for patients.
Interventions
DRUGButorphanol Injection
Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy
DRUGSaline
Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy
Sponsors
Beijing Tiantan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* ASA status I-11 * patients performing colonoscopy * sign the informed consent
Exclusion criteria
* BMI\>30, pregnant * diabetes * depression * patients dependent on opioids * hypertension poorly controlled * serious complications of important organs * obvious abdominal pain before colonoscopy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| visceral pain | 10 minutes after recovery | VAS score of visceral pain |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| visceral pain at 20 and 30 minutes after recovery | 20 and 30 minutes after recovery | VAS score of visceral pain |
Countries
China
Outcome results
None listed